Skip to main content

Daly Richard J's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Jun 5, 2024

Accession no.
0001161697-24-000254
Filed
Jun 5, 2024
Trade date
Jun 4, 2024
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $276.8K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Daly Richard JCIK 0001635393Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 4, 2024Common stock, par value $0.001 per shareMOption exerciseAcquired+40,000$4.01+$160,400252,147Direct
Jun 4, 2024Common stock, par value $0.001 per shareSSaleDisposed−17,323$15.98F1−$276,821.54234,824Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 4, 2024Common StockMOption exerciseDisposed−40,000$0.00$01,731,012Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Shares were sold on the open market in order to fund the exercise price and tax withholding of the exercise of the stock option.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)